A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Published today in the scientific…
Read More
Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma
A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma—a common childhood tumor with a low survival rate. Neuroblastoma is a cancer in children…
Read More
Statins tied to significantly lower death rate from ovarian cancer
(HealthDay)—Statin drugs, used for decades to treat high cholesterol, may also reduce deaths for women with ovarian cancer, a new study suggests. “These drugs are appealing as they are widely used, inexpensive, and well-tolerated in most patients. The associated reduction…
Read More
New research shows which ovarian cancer patients won’t benefit from immune-PARP combo
In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients won’t benefit…
Read More